Related Experiment Videos
Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study
D E Bernstein1, L Jeffers, E Erhardtsen
1Department of Hepatology, University of Miami School of Medicine, Florida, USA.
Gastroenterology
|December 12, 1997
Summary
Recombinant factor VIIa (rFVIIa) effectively corrected prolonged prothrombin time (PT) in nonbleeding cirrhotic patients. This study suggests rFVIIa is a promising treatment for coagulopathy in cirrhosis.
Area of Science:
- Hepatology
- Hematology
- Pharmacology
Background:
- Cirrhosis often causes coagulopathy, characterized by prolonged prothrombin time (PT) due to low factor VII levels.
- Current treatments for this coagulopathy are suboptimal.
- Recombinant factor VIIa (rFVIIa) is a potential therapeutic agent for correcting prolonged PT in cirrhotic patients.
Purpose of the Study:
- To evaluate the effectiveness of rFVIIa in nonbleeding cirrhotic patients with coagulopathy.
- To assess the safety and efficacy of different rFVIIa dosages.
Main Methods:
- A preliminary, single-center, dose-escalation trial was conducted.
- Ten cirrhotic patients with prolonged PT unresponsive to vitamin K were administered escalating doses of rFVIIa (5, 20, 80 µg/kg) over three weeks.
- Prothrombin time and adverse events were monitored.
Main Results:
- rFVIIa transiently corrected the mean prothrombin time to normal levels across all dosage groups.
- No adverse effects were observed during the trial.
- No evidence of disseminated intravascular coagulation was detected.
Conclusions:
- rFVIIa demonstrated effectiveness in transiently reversing prolonged PT in a select group of nonbleeding cirrhotic patients.
- The preliminary findings support further investigation in large-scale efficacy trials.
- rFVIIa shows potential as a safe and effective treatment for coagulopathy in cirrhosis.